MSMiguel Ángel Saavedra

Miguel Ángel Saavedra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Miguel Ángel Saavedra has a total of 322 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Burden and temporal trends attributable to low bone mineral density in Mexico, 1990–2023: a global burden of disease analysis

    by Pamela Munguía-Realpozo, Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Edith Ramírez-Lara, Miguel Ángel Saavedra-Salinas, Elizabeth Suárez-Belmont, Gustavo López-Gasca, Jorge Ayón-Aguilar, Máximo Alejandro García-Flores

  • Promoting the utilization of rheumatologic musculoskeletal anatomy: a 50-year travel log

    by Robert A. Kalish, Jeffrey R. Wohlgethan, Nancy Liu, José Alvarez Nemegyei, Pablo Villaseñor-Ovies, Miguel Ángel Saavedra, Cristina Hernández-Díaz, José Eduardo Navarro-Zarza, Virginia Pascual-Ramos, Esperanza Naredo, et al.

    This report traces the authors' long journey toward a deeper understanding of the anatomical basis of rheumatologic physical examination. Fifty years ago, one of the authors was struck by the prevalence of subcutaneous and deep bursitis and regional musculoskeletal pain syndromes at his new workplace, prompting studies of bursal swelling, lubrication, and the dynamics of distended superficial and deep bursae. Subsequently, a deficiency in anatomical knowledge was noted across multiple workshops at the American College of Rheumatology and elsewhere. Later, in a different setting, musculoskeletal anatomy workshops were held, based on cross-examination between rheumatology learners and instructors. Palpation was used in the upper extremity, and the spine and lower extremity were demonstrated through motion and self-palpation. Pre-workshop tests consistently revealed poor recall of musculoskeletal anatomy among trainees and practitioners, including orthopedic trainees. All questions were rated highly important in an international Delphi survey of anatomical items relevant to rheumatology. Subsequently, a self-examination method was developed to allow learners to practice, in privacy, the anatomical knowledge traditionally acquired. More recently, an international, unfunded, and enthusiastic study group comprising anatomists, rheumatologists, and ultrasonographers made independent observations of defined neck and upper extremity structures, including the elusive lower belly of omohyoid, the dorsal forearm muscle-tendon intersection, the concurrent contraction of anconeus and pronator teres, and dynamic aspects of the extensor apparatus of the fingers, the natatory ligament, the web spaces, and the intertendinous connections. In these studies, physical examination and ultrasound complemented each other. Thus, physical examination, rather than being replaced, should be strengthened. Key Points • We describe a sustained effort spanning more than 50 years to reinstate MSK anatomy as a basic competence for MSK conditions and general rheumatologic examination. • The initial studies focused on subcutaneous and deep bursae and on seminars regarding musculoskeletal pain syndromes and, much later, the anatomical basis of rheumatologic examination. • This was followed by a one-on-one assessment of rheumatology fellows' and practitioners' anatomical knowledge and by participatory MSK anatomy seminars held across the Americas with support from ILAR. • Subsequently, a method of self-examination was developed as an accessible way to reinforce anatomical learning. • Currently, independent physical examination and ultrasonography, along with dissection performed by anatomists, have resulted in a series of innovative and fruitful proof-of-concept studies.

  • Discordance in Patient and Physician's Perception of Disease Activity Among Idiopathic Inflammatory Myopathy Patients: Insights From the COVAD Study

    by Rudra P. Goswami, Parikshit Sen, Zoha Zahid Fazal, Jasmine Parihar, Yogesh Preet Singh, R. Naveen, James B. Lilleker, Mrudula Joshi, Vishwesh Agarwal, Arvind Nune, et al.


  • Systemic lupus erythematosus in critical care: A systematic review of ICU outcomes and management

    by Edith Ramírez-Lara, Claudia Mendoza-Pinto, Pamela Munguía-Realpozo, Miguel Ángel Saavedra-Salinas, Ivet Etchegaray-Morales, Jorge Ayón-Aguilar, Álvaro José Montiel-Jarquín, Socorro Martínez-Méndez


  • Active but not quiescent lupus nephritis during pregnancy is associated with a higher rate of adverse obstetric outcomes: Analysis of a prospective cohort

    by Miguel Ángel Saavedra, Tayde Sarahí Gracia‐Aréchiga, Dafhne Miranda‐Hernández, Antonio Sánchez, Michelle Arrucha‐Cozaya, María del Pilar Cruz‐Domínguez

    Objective: To compare the maternal‐fetal/neonatal outcome in patients with systemic lupus erythematosus (SLE) with and without lupus nephritis (LN) in remission or with active disease. Methods: A prospective cohort of pregnant patients with SLE (ACR 1997 criteria) was studied from January 2009 to December 2021. Demographic, clinical, biochemical, and immunological variables as well as the usual maternal‐fetal/neonatal complications were recorded. We compared four groups according to the status of SLE during pregnancy: patients with quiescent SLE without lupus nephritis, patients with active SLE without lupus nephritis, patients with quiescent lupus nephritis, and patients with active lupus nephritis. Statistical analysis included descriptive statistics, bivariate analysis, and Cox regression analysis. Results: A total of 439 pregnancies were studied, with a median age of 28 ± 6, SLE duration of 60 months (interquartile range 36–120). A higher frequency of maternal and fetal/neonatal complications was observed in patients with active SLE with or without lupus nephritis. Multivariate analysis showed that active LN was a risk factor for gestational hypertension (hazard ratios [HR] 1.95; 95% confidence intervals [CI]: 1.01–6.39), premature rupture of membranes (HR 3.56; 95% CI: 1.79–16.05) and more frequent cesarean section (HR 1.82; 95% CI: 1.13–2.94). Conclusion: LN is associated with a higher frequency of maternal complications, especially in those patients with active disease during pregnancy, and those maternal complications had an impact on poor fetal/neonatal outcomes. Strict control and timely care of LN could improve the obstetric prognosis.


  • Flares of autoimmune rheumatic disease following COVID‐19 infection: Observations from the COVAD study

    by Nimrat Kaur Sandhu, Naveen Ravichandraan, Arvind Nune, Jessica Day, Parikshit Sen, Elena Nikiphorou, Ai Lyn Tan, Mrudula Joshi, Sreoshy Saha, Samuel Katsuyuki Shinjo, et al.


  • The prognostic value of neutrophile/lymphocyte ratio and serum chemerin to predict maternal-fetal complications in pregnant systemic lupus erythematosus patients

    by Gabriela Medina, Francisco R González-Cortés, Antonio Sánchez-González, Juan G Vázquez-Rodríguez, Irvin Ordoñez-González, María P Jiménez-Arellano, Grettel García-Collinot, Susana I Morales-Montalvo, Oscar I Florez-Durante, María P Cruz-Domínguez, et al.

    Background: Pregnancy in SLE continues to be a challenge. The neutrophil-to-lymphocyte ratio (NLR) and chemerin are predictors of preeclampsia in the general population; however, their role as predictors of maternal-fetal complications in pregnant SLE patients has not been analyzed. Objective: To investigate the prognostic value of NLR and serum chemerin, to predict maternal-fetal complications in pregnant SLE patients, and compare both biomarkers among three study groups. Methods: Design: Analytical cross-sectional study of cases and controls with the following study groups: systemic lupus erythematosus (SLE), preeclampsia, and healthy. NLR and chemerin serum were determined between 20 and 25 weeks of gestation. Patients were evaluated every 4–6 weeks until pregnancy resolution. Maternal and fetal outcomes were registered. We employed Receiver Operating Characteristic (ROC) curves to validate prognostic values. Results: Seventy pregnant patients were included: 20 with SLE, 20 with preeclampsia, and 30 healthy pregnant women; NLR values were 4 (2.3–5.6) in SLE, 6 (4.6–9.2) in preeclampsia, and 2.8 (2.1–2.9) in the group of healthy women ( p = .0001). Chemerin levels were: 26 (15.3–56.2) in SLE, 96 (37.3–146.2) in preeclampsia, and 24.6 ng/mL (15.3–47.4) in the healthy group ( p = .007) Maternal complications were observed in 11 (55%), 20 (100%), and 8 (26%) per group, respectively. Thrombocytopenia was the most frequent complication in all pregnant women, followed by hypertensive disorders. Fetal complications were registered in 12 (60%), 16 (80%), and 2 (6.7%), respectively. Congenital malformations and prematurity were the most frequent fetal complications. NLR had good diagnostic accuracy in predicting maternal-fetal complications (AUROC 0.715) p = .015, CI 95% 0.56–0.86, cut-off point level: 2.9, sensitivity 61%, specificity 78%, positive predictive value (PPV) 65%, negative predictive value (NPV) 75%. Regarding chemerin, a cut-off point level >43 ng/mL had a sensitivity of 75%, specificity of 72% AUROC 0.75, p = .001, CI 95% 0.61–0.89, PPV 51.7% NPV 87.8%, meaning that 51.7% of patients with chemerin levels >43 ng/mL have or will have preeclampsia. Conclusion: The NLR may help predict maternal-fetal complications in SLE pregnancy, constituting a marker of subclinical inflammation. Chemerin levels may be associated with preeclampsia. These biomarkers could improve the care of SLE patients with timely intervention of potential complications during pregnancy.


  • In-hospital mortality and associated factors in patients with systemic lupus erythematosus: analysis over more than 11 years in a reference hospital center

    by Michelle Arrucha-Cozaya, Nuria Cecilia Zamora-Zúñiga, Dafhne Miranda-Hernández, Reyna Bustamante-González, Gabriela Martínez-Díaz, Drusila Tovar-Rodríguez, Berenice López-Zamora, María Del Pilar Cruz-Domínguez, Abraham Edgar Gracia-Ramos, Miguel Angel Saavedra

    Systemic lupus erythematosus (SLE) is a disease that affects the immune system, and it can lead to increased morbidity and mortality. The primary causes of mortality for individuals with SLE are disease activity, infections, drug toxicity, and other health conditions. The aim of this study is to estimate the mortality rate of patients with SLE who are hospitalized, describe the causes of death, and identify factors associated with mortality. The study was conducted at a referral hospital from 2009 to 2021, utilizing a nested case–control design. The records of patients with SLE who were hospitalized in the Department of Rheumatology were reviewed. Cases were identified as individuals who died during their hospitalization, while controls were those who were discharged alive during the same period. Elective hospitalizations were not included in the study. The primary causes of death were recorded, and demographic, clinical, laboratory, and immunological variables were analyzed as potential risk factors associated with in-hospital mortality. The study included 105 patients who died while hospitalized and 336 who were discharged alive. The estimated mortality rate was 10.93 deaths per 1000 hospital admissions per year. The leading causes of death were SLE activity (20%), infections (34.2%), or a combination of both (24.8%). Risk factors associated with in-hospital mortality were any infection (OR 2.5, CI 95% 1.2–5.2), nosocomial infections (OR 5.0, CI 95% 1.8–13.7), SLEDAI-2K > 2 (OR 2.0, CI 95% 1.02–3.8), lymphopenia (OR 2.1, CI 95% 1.01–4.6), anemia (OR 2.9, CI 95% 1.4–5.7), and thrombocytopenia (OR 3.3, CI 95% 1.7–6.4). Disease activity and infections, particularly nosocomial infections, are significant causes of mortality in hospitalized patients with SLE. Furthermore, hematological manifestations play a significant role in in-hospital mortality for these patients.


  • Influence of visceral adiposity on cardiovascular risk in patients with systemic sclerosis

    by Gabriela Martínez-Díaz, María Pilar Cruz-Domínguez, Berenice López Zamora, Jordan Ramirez-Facio, Gabriela Medina, Ricardo Xavier Munguía-Cruz, Miguel Angel Saavedra-Salinas, Michelle Arrucha-Cozaya, Olga Lidia Vera-Lastra, Ana Lilia Peralta-Amaro, et al.

    Systemic sclerosis (SSc) is an autoimmune disease characterized by systemic inflammation, endothelial dysfunction, generalized fibrosis and high cardiovascular mortality. The evaluation of cardiovascular risk through the visceral adiposity index (VAI) has been helpful due to its direct relationship to the body and visceral fat percentage. We evaluated the influence of body composition and anthropometrics on cardiovascular risk as measured by VAI in healthy controls (HC) and SSc. An analytical cross-sectional study of 66 participants (33 SSc and 33 HC), mean age 52.7 ± 10, 95% women, was conducted from August 2020 to January 2021. Inclusion criteria in cases were consecutive patients with SSc (ACR/EULAR 2013), 63.6% were diffuse cutaneous (dcSS) subtype, and 36.4 were limited cutaneous (lcSS) subtype. HC was matched by age and gender. Serum lipid profiles and InBody anthropometrics were analyzed and compared. We performed descriptive statistics, bivariate analysis with Student’s t, or Mann–Whitney U, correlation and chi-square according to the variable type and distribution. Total cholesterol was significantly higher in SSc than HC (345 vs 194, p = < 0.001). The BMI was higher in HC (26.2 vs 28.9, p < 0.001). Kilograms of muscle (19.8 vs 28.9, p < 0.001) and total fat (23.4 vs 28.9, p < 0.001) were lower in SSc patients compared to HC. VAI was similar when BMI < 25, but significantly higher when BMI > 25 in SSc than in HC (3 vs 1.9, p = 0.030). The increase in BMI at overweight or obese in SSc is associated with a significant increase in cardiovascular risk.